MTOR and non-small cell lung carcinoma: Taken together, these results provided molecular evidence that the PI3K/mTOR dual inhibitor, DHW-221, overcomes MDR via targeting P-gp and Akt-mediated FOXO3a nuclear translocation in NSCLC.